According to Vision Research Reports, the global point of care infectious disease testing market size was valued at US$ 2.3 billion in 2021 and is expected to reach around USD 4.1 billion by 2030 with a CAGR of 17% from 2022 to 2030.
According to Vision Research Reports, the global point of care infectious disease testing market size was valued at US$ 2.3 billion in 2021 and is expected to reach around USD 4.1 billion by 2030 with a CAGR of 17% from 2022 to 2030.
Growth Factors
Driven by the latest trends of consumer-centric services coupled with high demand for portable and rapid testing devices this market is expected to witness lucrative growth. Moreover, continuous rise in number cases of infectious diseases has boosted the advancements in point of care instruments sector thereby driving progress.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37876
Rising incidences & prevalence rates of communicable diseases coupled with increasing geriatric population that have lower immunity are attributive to upsurge the demand for better diagnostics in the market. Demand for these tests is specific in nature and pronounces the need for intensive R&D in order to treat several infections.
Disease Insights
Human Immunodeficiency Virus (HIV) POC tests accounted for the largest revenue share in 2016. Efforts taken up by various entities such as World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and major companies for contributing towards advancing and delivering sensitive and accurate devices are anticipated to enhance penetration of these devices in the coming years.
Demand for POC testing of influenza, TB and MDR-TB is expected to grow at a lucrative pace in the coming years as a consequence of rising incidence rates of these diseases. Moreover, the development of rapid RT-PCR tests for influenza that are better in the detection of the microorganisms than the conventional tests are anticipated to boost progress in this segment.
End-use Insights
Clinics accounted for the largest market share owing to the higher adoption of these devices and platforms in clinics. Moreover, increasing penetration of these devices in the clinics and associated facilities is attributive to the estimated share.
Assisted living healthcare facilities are anticipated to register the fastest growth in the coming years due to higher usage in this segment as a consequence of rising demand by the geriatric population base.
Regional Insights
North America dominated the point of care infectious disease testing market, particularly the U.S. holds the highest revenue share in the field of rapid and easy to use diagnostics, owing to factors such as the presence of substantial players, well-established healthcare framework. Moreover, the introduction of technological advances in this region supports the estimated revenue share.
However, Asia Pacific is expected to emerge as the fastest-growing region due to increment in R&D expenditure in patient-centric facilities in Japan and China. Furthermore, the dramatically increasing burden of chronic infectious diseases coupled with the presence of government initiatives aimed to promote early diagnosis are factors expected to fuel regional progress.
Companies in Asia are focusing on the development of novel assays, for instance, in May 2017, One BioMed and A*Star’s Genome Institute of Singapore established a joint lab venture for molecular diagnostic assay production. This collaboration is intended for the development of assays for the Asian clinical infectious disease testing market. These assays include tests for pediatric respiratory infections, mosquito-borne illnesses, and drug-resistant tuberculosis.
Key Players
Alere, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Siemens Healthineers, BD & Company, Chembio Diagnostics Inc., Trinity Biotech, Cardinal Health, Quest Diagnostics Inc., Bio-Rad Labs Inc., bioMérieux SA, Sight Diagnostics Ltd., Gene POC, Trivitron Healthcare, OJ-Bio Ltd., and Ortho-Clinical Diagnostics.
Market Segmentation
- Disease Outlook
- HIV POC
- Clostridium difficile POC
- HBV POC
- Pneumonia or Streptococcus associated infections
- Respiratory syncytial virus (RSV) POC
- HPV POC
- Influenza/Flu POC
- HCV POC
- MRSA POC
- TB and drug-resistant TB POC
- HSV (Herpes Simplex Virus) POC
- Other infectious disease POC
- End-Use Outlook
- Hospitals
- Clinics
- Home
- Assisted Living Healthcare Facilities
- Laboratories
- Others
- Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East and Africa (MEA)
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37876
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333